New data demonstrates SonoThera’s novel, ultrasound-mediated gene delivery (UMGD) platform’s ability to noninvasively provide safe, effective gene therapy delivery to liver. Presentation focuses on ...

New data demonstrates the ability of UMD technology to deliver genetic medicines, allowing for full-length human dystrophin protein expression in skeletal, heart and diaphragm muscle tissue in murine ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines, ...

New data demonstrates the ability of UMD technology to deliver genetic medicines, enabling full-length gene expression of Col4a5 in the treatment of X-Linked Alport Syndrome (XLAS) in murine and ...

SonoThera is entering a clinical execution phase, advancing multiple genetic medicine programs toward first-in-human studies. Lead clinical programs include Duchenne muscular dystrophy (DMD), ...

Presentation will provide late-breaking data on the Company’s novel, non-invasive, nonviral ultrasound-mediated gene therapy platform, being developed to deliver the next generation of safe and ...

SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced it has received exclusive, global, commercial licensing rights from ...

New preclinical data demonstrates the ability of SonoThera’s novel, nonviral UMD technology to deliver genetic medicines, allowing for full-length dystrophin protein expression in skeletal, cardiac ...

The MarketWatch News Department was not involved in the creation of this content. -- SonoThera is entering a clinical execution phase, advancing multiple genetic medicine programs toward ...

Oral and poster presentations will highlight SonoThera’s proprietary, nonviral, non-invasive approach using ultrasound-mediated delivery (UMD). In the treatment of DMD, data demonstrates the ability ...